STLN
Starling Oncology Inc.
STLN | NASDAQ
$6.53
-$0.12 (-1.80%)
At close: Oct 30, 2026, 3:59 PM ET
$6.41
-$0.12 (-1.84%)
Pre-market:
Nov 2, 2026, 4:48 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 |
|---|---|
Revenue | 502.73M |
Cost of Revenue | 426.29M |
Gross Profit | 76.44M |
Operating Income | -36.08M |
Interest Income | n/a |
Pretax Income | -60.74M |
Net Income | -60.61M |
Selling & General & Admin | 105.57M |
Research & Development | n/a |
Other Expenses | 6.94M |
Operating Expenses | 112.52M |
Interest Expense | 11.28M |
Selling & Marketing Expenses | n/a |
Cost & Expenses | 538.81M |
Income Tax Expense | -131K |
Shares Outstanding (Basic) | 92.39M |
Shares Outstanding (Diluted) | 92.39M |
EPS (Basic) | -0.54 |
EPS (Diluted) | -0.54 |
EBITDA | -42.52M |
EBIT | -49.46M |
Depreciation & Amortization | 6.94M |
Add to Watchlist
Select watchlists to add or remove STLN